We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has expressed concern that stability failures and other out-of-specification results for creams manufactured by Taro Pharmaceutical Industries did not prompt the generic-drug maker to withdraw the products or shorten the expiration period on the products, according to a warning letter.